Saturday 17 October 2026
Export XRTX’s income statement to Excel — free account
XORTX Therapeutics Inc.
XRTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 10.5% and free cash flow fell 318.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.24
0.18
−12.68%
Follow XRTX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
2.11 | 3.53 | 4.93 | 7.21 | 28.78 | 1.99 | 0.62 | 1.09 | — |
Net Debt/EBITDA |
0.28 | 0.62 | 0.58 | 1.02 | 5.19 | 0.12 | 1.34 | 0.80 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.09% | 0.00% | 0.00% | 4.67% | 3.42% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.24) | 0.13 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
1.04 | 1.11 | 3.05 | 1.16 | 3.67 | 0.57 | 0.29 | 0.24 | — |
Capex/Depreciation |
(0.49) | (0.33) | (0.33) | (0.79) | (2.22) | (0.70) | 0.00 | 0.00 | — |
Interest Coverage |
— | — | — | 97.26 | (647.09) | (109.69) | (30.43) | (103.78) | — |
| (98.00%) | (83.06%) | (37.08%) | (75.86%) | (18.45%) | (247.50%) | (1,316.93%) | (7,549.59%) | — | |
| (78.38%) | (69.30%) | (24.19%) | (51.53%) | (13.67%) | (75.31%) | (54.81%) | (596.89%) | — | |
ROIC |
(166.80%) | (298.29%) | (316.40%) | 0.00% | 0.00% | (80.42%) | 0.00% | 0.00% | — |
Return on Tangible Assets |
(379.96%) | (169.62%) | (66.06%) | (81.45%) | (8.49%) | (125.70%) | 126.17% | (4,725.78%) | — |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.07 | 0.04 | 0.03 | 0.02 | 0.01 | 0.10 | 0.25 | 0.23 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
Free Cash Flow per Share |
(2.98) | (6.46) | (16.72) | (30.44) | (22.25) | (3.74) | (0.23) | (1.16) | — |
Cash per Share |
0.91 | 4.30 | 8.70 | 35.25 | 68.75 | 0.86 | 1.01 | 1.19 | — |
Shareholders Equity per Share |
2.20 | 5.79 | 11.71 | 23.64 | 61.04 | 6.33 | (0.27) | 0.40 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
2.20 | 5.79 | 11.71 | 23.64 | 61.04 | 6.33 | (0.27) | 0.40 | — |
Free Cash Flow |
(2.82) | (3.72) | (6.63) | (9.01) | (4.87) | (0.55) | (0.14) | (0.68) | — |
Working Capital |
0.66 | 1.92 | 3.24 | 9.38 | 15.54 | 0.76 | (0.38) | 0.06 | — |
Capital Expenditures |
(0.06) | (0.04) | (0.05) | (0.05) | (0.03) | (0.01) | (0.01) | (0.03) | — |
Net Current Asset Value |
0.66 | 1.92 | 3.24 | 5.52 | 11.87 | 0.76 | (0.38) | 0.03 | — |
| Other line items | |||||||||
Quick Ratio |
1.58 | 3.29 | 4.25 | 6.96 | 26.97 | 0.22 | 0.62 | 1.09 | — |
Depreciation/Fixed assets |
3.02 | 3.38 | 5.85 | 0.63 | 0.00 | 0.00 | 66.33 | 27.57 | — |
Cash ROIC |
(95.76%) | (63.98%) | (81.95%) | (51.65%) | (17.15%) | (52.03%) | (28.78%) | (70.27%) | — |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(2.92) | (6.39) | (16.61) | (30.28) | (22.11) | (3.67) | (0.23) | (1.16) | — |
Capex per Share |
(0.06) | (0.07) | (0.12) | (0.15) | (0.15) | (0.07) | 0.00 | 0.00 | — |
Average Receivables |
0.05 | 0.04 | 0.07 | 0.06 | 0.04 | 0.03 | 0.02 | 0.02 | — |
Average Payables |
0.35 | 0.22 | 0.86 | 1.00 | 0.67 | — | — | — | — |
Average Assets |
3.39 | 4.78 | 8.92 | 14.98 | 9.65 | 1.27 | 0.88 | 0.47 | — |
Average Common Equity |
2.71 | 3.99 | 5.82 | 10.18 | 7.15 | 0.39 | 0.04 | 0.04 | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Columns are period end dates